Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 24;26(5):1935.
doi: 10.3390/ijms26051935.

Clinical Importance of Amyloid Beta Implication in the Detection and Treatment of Alzheimer's Disease

Justyna Pokrzyk  1 , Agnieszka Kulczyńska-Przybik  1 , Ewa Guzik-Makaruk  2 , Izabela Winkel  3 , Barbara Mroczko  1   4
Affiliations
Review

Clinical Importance of Amyloid Beta Implication in the Detection and Treatment of Alzheimer's Disease

Justyna Pokrzyk et al. Int J Mol Sci. .

Abstract

The role of amyloid beta peptide (Aβ) in memory regulation has been a subject of substantial interest and debate in neuroscience, because of both physiological and clinical issues. Understanding the dual nature of Aβ in memory regulation is crucial for developing effective treatments for Alzheimer's disease (AD). Moreover, accurate detection and quantification methods of Aβ isoforms have been tested for diagnostic purposes and therapeutic interventions. This review provides insight into the current knowledge about the methods of amyloid beta detection in vivo and in vitro by fluid tests and brain imaging methods (PET), which allow for preclinical recognition of the disease. Currently, the priority in the development of new therapies for Alzheimer's disease has been given to potential changes in the progression of the disease. In light of increasing amounts of data, this review was focused on the diagnostic and therapeutic employment of amyloid beta in Alzheimer's disease.

Keywords: Alzheimer’s disease; amyloid PET; amyloid beta; amyloid blood; neurodegenerative disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Tested immunotherapy against amyloid beta.
See this image and copyright information in PMC

References

    1. Akasaka-Manya K., Manya H. The Role of APP O-Glycosylation in Alzheimer’s Disease. Biomolecules. 2020;10:1569. doi: 10.3390/biom10111569. - DOI - PMC - PubMed
    1. Chen G.F., Xu T.H., Yan Y., Zhou Y.R., Jiang Y., Melcher K., Xu H.E. Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development. Acta Pharmacol. Sin. 2017;38:1205–1235. doi: 10.1038/aps.2017.28. - DOI - PMC - PubMed
    1. Marsh S.E., Blurton-Jones M. Examining the Mechanisms That Link β-Amyloid and α-Synuclein Pathologies. Alzheimer’s Res. Ther. 2012;4:11. doi: 10.1186/alzrt109. - DOI - PMC - PubMed
    1. Zhang Y., Chen H., Li R., Sterling K., Song W. Amyloid β-Based Therapy for Alzheimer’s Disease: Challenges, Successes and Future. Signal Transduct. Target. Ther. 2023;8:248. doi: 10.1038/s41392-023-01484-7. - DOI - PMC - PubMed
    1. Niu Z., Gui X., Feng S., Reif B. Aggregation Mechanisms and Molecular Structures of Amyloid-β in Alzheimer’s Disease. Chem. A Eur. J. 2024;30:e202400277. doi: 10.1002/chem.202400277. - DOI - PubMed

LinkOut - more resources